Acs Research - Theorylab

It started with a tweet, and in less than a month scientists, clinicians, and patients from over 100 centers in the United States and Canada came together to learn about the impact of COVID-19 on cancer patients. The COVID-19 and Cancer Consortium was formed to “collect granular, uniformly organized information to stimulate translational science and also to arm our treating providers with the most comprehensive and scientifically accurate evidence as rapidly as possible on cancer patients affected with the virus.” It has already paid dividends. The consortium has already published evidence in a new paper in Lancet titled, “Clinical impact of COVID-19 on patients with cancer: a cohort study.” One of the principal authors of that paper joined us to discuss the work of the consortium. Dimpy Shah, PhD—an American Cancer Society research grantee and Assistant Professor of Epidemiology at Mays Cancer Center, home to UT Health San Antonio MD Anderson—is a founding member of the COVID-19 and Cancer Consortium